The invention relates to 5-HT receptor modulators, particularly
5-HT.sub.2B antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine
compounds represented by Formula I, II and III, and uses thereof for
treating conditions including pulmonary arterial hypertension, congestive
heart failure, and hypertension.